Axonal sprouting following lesions of the rat substantia nigra.
Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Symptoms do not appear until most nigral neurons are lost, implying that compensatory mechanisms are present. Sprouting has been proposed as one of these mechanisms. This study quantified the extent of compensatory axonal sprouting following injury of dopaminergic neurons within the substantia nigra pars compacta. Specifically, the extent of the axonal arbour and axonal varicosity morphology was measured after partial destruction (with 6-hydroxydopamine) of the substantia nigra of the adult male rat. Four months later, the substantia nigra was injected with the anterograde neuronal tracer dextran-biotin to trace the full extent of individual axons. An unbiased estimate of neuron number was performed in each animal. This demonstrated nigral neuronal loss ranging from 10 to 90% on the side that received the injection whilst a 7% reduction was observed in the side contralateral to the lesion. Coincident with this loss, some nigral neurons lose tyrosine hydroxylase expression. Vigorous axonal sprouting was observed in the terminal arbours of lesioned animals and was associated with an increased axonal varicosity size. Axonal varicosities and branching points were primarily confined to the dorsal 1.5mm of the caudate-putamen, an area predominantly innervated by nigral neurons. It appears that dopaminergic neurons were responsible for this sprouting because the density of dopamine transporter immunoreactive varicosities in the caudate-putamen was maintained until about a 70% loss of neurons. It was concluded that substantial compensation in the form of sprouting and new dopaminergic synapse formation occurs following lesions of the substantia nigra pars compacta.
Finkelstein
D I
DI
Department of Medicine, Monash University, Clayton 3168, Victoria, Australia.
Stanic
D
D
Parish
C L
CL
Tomas
D
D
Dickson
K
K
Horne
M K
MK
D018663:Adrenergic Agents / Q000494:pharmacology; D000818:Animals; D001369:Axons / Q000502:physiology* / Q000648:ultrastructure; D002352:Carrier Proteins / Q000502:physiology; D004298:Dopamine / Q000502:physiology; D050483:Dopamine Plasma Membrane Transport Proteins; D008297:Male; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D008854:Microscopy, Electron; D017072:Neostriatum / Q000502:physiology / Q000648:ultrastructure; D009419:Nerve Tissue Proteins; D009473:Neuronal Plasticity / Q000502:physiology*; D016627:Oxidopamine / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000503:physiopathology; D017729:Presynaptic Terminals / Q000502:physiology / Q000648:ultrastructure; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration / Q000502:physiology*; D013378:Substantia Nigra / Q000502:physiology* / Q000648:ultrastructure
D018663:Adrenergic Agents; D002352:Carrier Proteins; D050483:Dopamine Plasma Membrane Transport Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D016627:Oxidopamine; D004298:Dopamine